SGLT2 inhibition is a type of treatment for type 2 diabetes that works by blocking the action of the sodium-glucose cotransporter 2 (SGLT2) protein in the kidneys. This protein is responsible for reabsorbing glucose from the urine back into the bloodstream, so by inhibiting its action, more glucose is excreted in the urine, leading to lower blood sugar levels. SGLT2 inhibitors are a relatively new class of medications and have been shown to be effective in reducing blood sugar levels, as well as offering potential benefits for heart and kidney health.